The promise of combining CDK4/6 inhibition with hormonal therapy in the first-line treatment setting for metastatic or recurrent endometrial adenocarcinoma
Isabelle Ray-Coquard, Bradley J Monk, Domenica Lorusso, Haider Mahdi, Vivek Upadhyay, Regina Graul, Amreen Husain, Mansoor Raza Mirza, Brian Slomovitz · 2023
Read The promise of combining CDK4/6 inhibition with hormonal therapy in the first-line treatment setting for metastatic or recurrent endometrial adenocarcinoma by Isabelle Ray-Coquard, Bradley J Monk, Domenica Lorusso, Haider Mahdi, Vivek Upadhyay, Regina Graul, Amreen Husain, Mansoor Raza Mirza, Brian Slomovitz (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10804003.txt.
Description
Isabelle Ray-Coquard and eight co-authors review a treatment pairing for endometrial cancer in two thousand twenty-three. The cancer, when it spreads or returns, is often incurable, and first-line chemotherapy can be harsh. The uterine lining cancer at issue is sensitive to hormones, but hormone therapy alone often stops working.
The authors discuss adding CDK4/6 inhibitors, a targeted drug class, to hormonal therapy. Early clinical evidence suggests the pairing is well tolerated and effective in select patients. Few endocrine options are approved for this setting, so the need is unmet. The authors argue the combination could become an important first-line choice for low-grade advanced or recurrent cases. The piece is a review of evidence, not a new trial.
Catalog record
| CREATOR | Isabelle Ray-Coquard, Bradley J Monk, Domenica Lorusso, Haider Mahdi, Vivek Upadhyay, Regina Graul, Amreen Husain, Mansoor Raza Mirza, Brian Slomovitz |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 21 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |